Dose range
6 → 36 mg/day
Route
Oral tablet, once daily, no food restriction
Indication(s)
Chronic weight management (March 2026)

Titration schedule

StepDoseDurationNotes
16 mg/dayWeeks 1-4Starter
212 mg/dayWeeks 5-12
324 mg/dayWeeks 13-20
436 mg/dayWeek 21+Maximum

Important notes

  • This FDA-approved drug dosing chart is intended as a reference for clinicians and patients reviewing protocols, not a substitute for individualized prescriber guidance.
  • FDA-approved label dosing.
  • Compounded versions, where applicable, must be prepared by a licensed 503A or 503B compounding pharmacy. The April 14, 2026 FDA action restricted salt-form active ingredients.

References

  1. Foundayo (orforglipron) prescribing information / clinical literature.
  2. FDA Section 503A Interim Bulk Drug Substances List, updated April 14, 2026.
  3. USP <797>: Pharmaceutical Compounding — Sterile Preparations.